We demonstrated that ATTO-647N- and 68Ga-conjugated S1 can specifically target MSLN-positive tumours in vivo, highlighting its potential for non-invasive imaging of MSLN as a companion test for MSLN-targeting therapies. Here, MSLN is linked to neoplasm.